BIOXYNE LIMITED — Annual Report 2021

Aug 30, 2021

==> picture [164 x 64] intentionally omitted <==

ASX Announcement 31 August 2021

Attached is the Appendix 4E and Preliminary Financial Report for the Year ended 30 June 2021.

The Appendix 4E and Preliminary Financial Report have been approved for release by the Board.

==> picture [161 x 74] intentionally omitted <==

Anthony Ho Chairman

Bioxyne Limited ABN 97 084 464 193, Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000 Telephone +61 2 9078 8180 E info@bioxyne.com W www.bioxyne.com

==> picture [164 x 63] intentionally omitted <==

BIOXYNE LIMITED

ABN 97 084 464 193

The Companies Announcements Office The Australian Securities Exchange Limited SYDNEY

Date: 31 August 2021

APPENDIX 4E PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2021

This preliminary financial report by Bioxyne Limited (“Bioxyne” or “the Company”) is provided to the Australian Securities Exchange (ASX) under ASX listing Rule 4.3A are as follows:-

1. The reporting period is twelve months to 30 June 2021. The previous reporting period was twelve months to 30 June 2020.

2. Key information relating to the above reporting periods is as follows:-

	30 June 2021 $	30 June 2020 $	% change
Revenue from ordinary activities Loss from ordinary activities after tax attributable to members Net loss attributable to members Proposed dividend Net tangible assetsper issued security	2,222,834 (425,725) (425,725) - 0.003	2,399,859 (593,095) (593,095) - 0.004	(7.4) +28% +28% -

• 3 to 6. See attached financials.

7. No dividends have been paid or are proposed.

8. There is no dividend reinvestment plan.

9. Net tangible assets per security $0.003 (2020; $0.004).

10. There has been no acquisition or disposal of any entities occurring during the financial year.

11. The Company has no associates or joint venture entities

12. Any other significant information needed by an investor to make an informed assessment of the Group’s financial performance and financial position.

Included in this document.

13. The Company is not a foreign entity.

14. Commentary on the results

See commentary and the attached financials.

15. The report is based on financial statements which are in the process of being audited.

The Appendix 4E should be read in conjunction with the accompanying Preliminary Final Report.

1

==> picture [157 x 61] intentionally omitted <==

COMMENTARY ON RESULTS FOR THE YEAR

REVENUE

The Group’s core revenue continued to be from the sale of the Group’s patented probiotic Lactobacillus fermentum VRI-003 (PCC®) in the international market in FY 2021. International sales of PCC® for FY 2021 of $1,815,462 (2020: $2,142,798) were down 15.3% on the prior year principally due to timing with a scheduled June 2021 shipment being delayed until the new financial year.

Revenue from direct sales in the markets where the Group holds direct selling licences, Indonesia and Malaysia, was severely impacted by COVID-19 this financial year with limited sales activity. Indonesia has had some ongoing success in moving sales online.

The Company successfully achieved proof of concept in incorporating its proprietary probiotic PCC® into its powder supplements during the year and will fulfill an order of ColosNZ to South East Asia with value ~$312k in Q1 FY 2022. It is expected that PCC® will be incorporated into future product revisions augmenting the product with added unique combination of probiotics for oral (probiotics K12) and gut health (probiotics PCC).

EXPENDITURE

Expenditure decreased over the prior year to $1,619,516 (2020: $1,948,772) with cost reductions across the board. Both years suffered from impairment charges, $154,423 in 2021 given product reaching expiry dates before projected deferred direct sales, and $212,126 in 2020 relating to goodwill and product development costs, both years attributable to market closures due to COVID-19.

Research and development (R&D) expenditure continued from the prior year with the Company extrapolating the successful incorporation of the Company’s proprietary strain of probiotics - PCC® into the Company’s powdered products. This new technology opens new opportunities for Bioxyne to bring the significant benefits of its clinically tested probiotic to its range of products designed to improve general health and immune support.

The loss for the year was $425,725 a 28% improvement over the prior year loss of $593,095 and a 16% improvement before impairment write offs in both years.

BALANCE SHEET

The net assets of the group declined to $2,003,823 as at 30 June 2021 (2020: $2,609,221), being attributable to the result for the year, including the impairment charge referred to above.

CASHFLOW

The Group reported a small positive operating cash flow for the year of $53,134 (2020: inflow $52,055), reflecting operating results and receivable collections during the year. A commendable outcome in a challenging COVID-19 year.

Cash at the end of the year was approximately $1.6 million.

OUTLOOK

The 2021 year was largely on hold in terms of operational performance being adversely impacted by COVID-19 in its direct sales markets of Malaysia and Indonesia.

As a consequence the Company is focused on developing other channels to market and is actively looking at acquisition opportunities to accelerate its growth.

2

==> picture [164 x 64] intentionally omitted <==

Bioxyne Limited and controlled entities

Consolidated Statement of Profit or Loss and Other Comprehensive Income For the Year Ended 30 June 2021

Notes Revenue from continuing operations Sale of goods 3 Other income 4 Cost of goods sold Expenses Research and development Personnel costs Business development Marketing Professional fees Compliance costs Non-executive director fees General and administration Depreciation-right-of-use assets Impairment of intangible assets Impairment of inventory Foreign exchange loss Borrowing costs Loss before income tax Income tax 5 Other comprehensive income for the year Total comprehensive loss for the year Loss is attributable to: Members of Bioxyne Limited Earnings per share From continuing operations - Basic loss per share 26 - Diluted loss per share 26	2021 2020 $ $ 2,110,377 2,259,264 112,457 140,595 (1,029,043) (1,044,181) (89,726) (130,243) (391,728) (442,289) (171,618) (311,236) (42,199) (41,361) (143,374) (167,705) (104,514) (126,134) (236,127) (212,126) (200,152) (175,633) (49,899) (71,815) - (212,462) (154,423) (50,737) (34,072) - (1,684) (7,032)
	(425,725) (593,095) - - - -
	(425,725) (593,095)
	(425,725) (593,095)
	Cents Cents (0.07) (0.09) (0.07) (0.09)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

3

==> picture [177 x 68] intentionally omitted <==

Bioxyne Limited and controlled entities Consolidated Statement of Financial Position As at 30 June 2021

Notes ASSETS Current Assets Cash and cash equivalents 6 Trade receivables 7 Current tax receivables 8 Other current assets 9 Inventories 10 Total Current Assets Non-Current Assets Intangible assets 11 Plant and equipment 12 Right-of-use assets 13 Other financial assets 14 Total Non-Current Assets Total Assets LIABILITIES Current Liabilities Trade and other payables 15 Lease liabilities 13 Provisions 16 Total Current Liabilities Total Non-Current Liabilities Total Liabilities Net Assets EQUITY Contributed equity 17 Reserves 18 Accumulated losses 18 Capital and reserves attributable to owners of Bioxyne Limited Non-controlling interests 19 Equity	2021 2020 $ $ 1,602,210 1,747,886 335,334 304,429 28,813 13,641 174,539 236,226 439,517 767,942
	2,580,413 3,070,197
	30,269 30,269 130,358 169,255 7,530 65,618 - -
	168,157 265,142
	2,748,570 3,335,339
	731,728 658,657 - 47,462 13,019 20,000
	744,748 726,119
	- -
	744,748 726,119
	2,003,822 2,609,220
	62,177,536 62,177,536 (55,749) 123,924 (60,170,826) (59,745,101)
	1,950,961 2,556,359 52,861 52,861
	2,003,822 2,609,220

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

4

==> picture [177 x 68] intentionally omitted <==

Bioxyne Limited and controlled entities Consolidated Statement of Changes in Equity For the year ended 30 June 2021

2021 At 30 June 2020 Total comprehensive loss for the year Movement in foreign translation currency reserve At 30 June 2021 2020 At 30 June 2019 Total comprehensive loss for the year Movement in foreign translation currency reserve Transfer from share based payments At 30 June 2020	Contributed equity Accumulated losses Share based payment reserve Foreign currency translation reserve Non- controlling Interests $ $ $ $ $	Total $
	62,177,536 (59,745,101) - 123,924 52,861	2,609,220
	- (425,725) - -	(425,725)
	- - (179,673) -	(179,673)
	62,177,536 (60,170,826) (55,749) 52,861	2,003,822
	Contributed equity Accumulated losses Share based payment reserve Foreign currency translation reserve Non- controlling Interests $ $ $ $ $	Total $
	62,177,536 (59,196,768) 44,762 63,705 52,861	3,142,096
	- (593,095) - - -	(593,095)
	- - - 60,219 -	60,219
	- 44,762 (44,762) - -	-
	62,177,536 (59,745,101) - 123,924 52,861	2,609,220

The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

5

==> picture [177 x 68] intentionally omitted <==

Bioxyne Limited Consolidated Statement of Cash Flows For the year ended 30 June 2021

Notes Cash flows from operating activities Receipts of other income (inclusive of goods and services tax) Payments to suppliers and employees (inclusive of goods and services tax) Research and development tax rebate Interest received Net cash inflow/(outflow) from operating activities 23 Cash flow from investing activities Purchase of plant and equipment Net cash outflow from investing activities Cash flows from financing activities Repayment of lease liabilities Net cash outflow from financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the financial year Foreign exchange adjustment to cash balance Cash and cash equivalents at end of the year 6	2021 2020 $ $ 2,095,015 2,816,647 (2,060,547) (2,812,841)
	34,468 3,806
	- 13,757 18,665 34,492
	53,134 52,055
	- (33,662)
	- (33,662)
	(46,783) (52,325)
	(46,783) (52,325)
	6,351 (33,932) 1,747,886 1,767,909 (152,027) 13,909
	1,602,210 1,747,886

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

6

Bioxyne Limited Notes to the Financial Statements

For the year ended 30 June 2021

1. Bioxyne Limited and controlled entities - Summary of significant accounting policies

(a) Basis of preparation

Reporting Entity

Bioxyne Limited is a company limited by shares, incorporated and domiciled in Australia.

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standard Board and the Corporations Act 2001 .

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards. Material accounting policies adopted in the preparation of this financial report are presented below. They have been consistently applied unless otherwise stated.

The financial report has been prepared on an accruals basis and is based on historical costs, except for selected financial assets for which the fair value basis of accounting has been applied.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 2.

(b) Parent entity information

In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated only. Supplementary information about the parent entity is disclosed in Note 28.

(c) Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Bioxyne Limited ('company' or 'parent entity') as at 30 June 2021 and the results of all subsidiaries for the year then ended. Bioxyne Limited and its subsidiaries together are referred to in these financial statements as the 'consolidated entity'.

7

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1 Summary of significant accounting policies (continued)

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Non-controlling interest in the results and equity of subsidiaries are shown separately in the statement of profit or loss and other comprehensive income, statement of financial position and statement of changes in equity of the consolidated entity. Losses incurred by the consolidated entity are attributed to the non-controlling interest in full, even if that results in a deficit balance.

Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

(d) Operating segments

Operating segments are presented using the ‘management approach’, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

(e) Foreign currency translation

(i) Functional and presentation currency

The functional and presentation currency of the Group is Australian dollars.

Foreign currency transactions are translated into the functional currency using the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the end of the reporting period. Foreign exchange gains and losses resulting from settling foreign currency transactions, as well as from restating foreign currency denominated monetary assets and liabilities, are recognised in profit or loss, except when they are deferred in other comprehensive income as qualifying cash flow hedges or where they relate to differences on foreign currency borrowings that provide a hedge against a net investment in a foreign entity.

Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when fair value was determined.

8

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1 Summary of significant accounting policies (continued)

Items included in the financial statements of the Group’s operations are measured using the currency of the primary economic environment in which it operates (‘the functional currency’). The financial statements are presented in Australian dollars, which is the Group’s functional and presentation currency.

(ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates ruling at the date of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Profit or Loss and Other Comprehensive Income.

(f) Revenue recognition

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods to a customer. The consolidated entity recognises revenue when the goods are shipped.

Sale of goods

Revenue from sale of goods is recognised at the point in time when the customer obtains control of the goods, which is generally at the time of delivery.

Interest income

Interest income is recognised as interest accrues using the effective interest method. The effective interest method uses the effective interest rates which is the rate that exactly discounts the estimated future cash receipts over the expected future life of the financial asset.

When a receivable is impaired, the Group reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount as interest income. Interest income on impaired loans is recognised using the original effective interest rate.

Research and Development Tax Incentive

Research and Development Tax Incentive claims are recognised as other income in the period to which the incentive claims relate.

(g) Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.

Government grants relating to costs are deferred and recognised in the profit and loss over the period necessary to match them with the costs that they are intended to compensate.

9

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1. Summary of significant accounting policies (continued)

(h) Income tax

The income tax expense or revenue for the period is the tax payable on the current period’s taxable income based on the income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax base of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.

Deferred tax assets and liabilities are recognised for all temporary differences, between carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases, at the tax rates expected to apply when the assets are recovered or liabilities settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. Exceptions are made for certain temporary differences arising on initial recognition of an asset or a liability if they arose in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit.

Deferred tax assets are only recognised for deductible temporary differences and unused tax losses if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax assets and liabilities are not recognised for temporary differences between the carrying amount and tax bases of investments in subsidiaries, associated and interests in joint ventures where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

(i) Fair value of assets and liabilities

The Group measures some of its assets and liabilities at fair value on either a recurring or non-recurring basis, depending on the requirements of the applicable Accounting Standard.

As fair value is a market-based measure, the closest equivalent observable market pricing information is used to determine fair value. Adjustments to market values may be made having regard to the characteristics of the specific asset or liability. The fair values of assets and liabilities that are not traded in an active market are determined using one or more valuation techniques. These valuation techniques maximise, to the extent possible, the use of observable market data.

To the extent possible, market information is extracted from either the principal market for the asset or liability (i.e. the market with the greatest volume and level of activity for the asset or liability) or, in the absence of such a market, the most advantageous market available to the entity at the end of the reporting period (i.e. the market that maximises the receipts from the sale of the asset or minimises the payments made to transfer the liability, after taking into account transaction costs and transport costs).

For non-financial assets, the fair value measurement also takes into account a market participant’s ability to use the asset in its highest and best use or to sell it to another market participant that would use the asset in its highest and best use.

10

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1 Summary of significant accounting policies (continued)

The fair value of liabilities and the entity’s own equity instruments (excluding those related to share-based payment arrangements) may be valued, where there is no observable market price in relation to the transfer of such financial instrument, by reference to observable market information where such instruments are held as assets. Where this

information is not available, other valuation techniques are adopted and, where significant, are detailed in the respective note to the financial statements.

(j) Leases

Right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the consolidated entity expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

Lease liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the consolidated entity's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

(k) Impairment of assets

At the end of each reporting period the Group assesses whether there is any indication that individual assets are impaired. Where impairment indicators exist, recoverable amount is determined and impairment losses are recognised in profit or loss where the asset's carrying value exceeds its recoverable amount. Recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purpose of assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

11

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1 Summary of significant accounting policies (continued)

Where it is not possible to estimate the recoverable amount for an individual asset, the recoverable amount is determined for the cash generating unit to which the asset belongs.

(l) Cash and cash equivalent

For the purposes of the Statement of Cash Flows, cash and cash equivalents includes cash on hand and at bank, deposits held at call with financial institutions, other short-term, highly liquid investments with maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts.

(m) Trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any provision for impairment. Trade receivables are generally due for settlement within 30 days.

The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for credit losses.

(n) Inventories

Raw materials, work in progress and finished goods are stated at the lower of cost and net realisable value on a 'first in first out' basis. Cost comprises of direct materials and delivery costs, direct labour, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity, and, where applicable, transfers from cash flow hedging reserves in equity. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable.

Stock in transit is stated at the lower of cost and net realisable value. Cost comprises of purchase and delivery costs, net of rebates and discounts received or receivable.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

(o) Trade and other payables

Trade and other payables represent liabilities for goods and services provided to the Group prior to the year end and which are unpaid. These amounts are unsecured and are usually paid within 30 days of recognition.

(p) Provisions

Provisions for legal claims, service warranties and make good obligations are recognised when the Group has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are not recognised for future operating losses.

12

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1 Summary of significant accounting policies (continued)

(q) Employee benefits

(i) Wages and salaries and annual leave

Liabilities for wages and salaries, including non-monetary benefits and annual leave expected to be settled within 12 months of the end of the reporting period are recognised in other payables in respect of employees' services rendered up to the end of the reporting period and are measured at amounts expected to be paid when the liabilities are settled.

(ii) Retirement benefit obligations

The Group does not maintain a company superannuation plan. The Group makes fixed percentage contributions for all Australian resident employees to complying third party superannuation funds. The Group's legal or constructive obligation is limited to these contributions.

Contributions to complying third party superannuation funds are recognised as an expense as they become payable. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

(iii) Share - based payments

The fair value of options granted under the Employee Share Option Plan “ESOP” is recognised as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which the employees become unconditionally entitled to the options.

The fair value at grant date is independently determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option.

The fair value of the options granted is adjusted to reflect market vesting conditions, but excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. At each reporting date, the entity revises its estimate of the number of options that are expected to become exercisable. The employee benefit expense recognised each period takes into account the most recent estimate. The impact of the revision to original estimates, if any, is recognised in the Statement of Profit or Loss and Other Comprehensive Income with a corresponding adjustment to equity.

Where the terms of options are modified, the expense continues to be recognised from grant date to vesting date as if the terms had never been changed. In addition, at the date of the modification, a further expense is recognised for any increase in fair value of the transaction as a result of the change.

Upon the exercise of options, the balance of the share based payments reserve relating to those options is transferred to share capital and the proceeds received, net of any directly attributable transaction costs, are credited to share capital.

13

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1. Summary of significant accounting policies (continued)

(r) Contributed equity

Costs directly attributable to the issue of new shares are shown as a deduction from the equity as a deduction proceeds net of any income tax benefit. Costs directly attributable to the issue of new shares or options associated with the acquisition of a business are included as part of the purchase consideration.

(s) Goods and services tax (GST)

Revenues, expenses and assets are recognised net GST, except where the GST incurred on the purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item.

Receivables and payables are stated with the amount of GST included. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the Statement of Financial Position.

Cash flows are included in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to, the taxation authority, are classified as operating cash flows.

(t) Plant and equipment

Each class of plant and equipment is carried at cost or fair value as indicated less, where applicable, any accumulated depreciation and impairment losses. Plant and equipment are measured on the cost basis.

Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the company and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Depreciation

The depreciable amount of all fixed assets is depreciated on a diminishing value basis over the asset’s useful life to the company commencing from the time the asset is held ready for use.

Depreciation is calculated on a diminishing-value basis over the estimated useful life of the assets as follows:

Plant and equipment – ranging from 3 to 7 years Software – 3 years Leasehold improvements – 5 years

An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount.

(u) Intangible assets

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses

14

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

1 Summary of significant accounting policies (continued)

recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

Goodwill

Goodwill arises on the acquisition of a business. Goodwill is not amortised. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit or loss and are not subsequently reversed.

Research and development

Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the consolidated entity is able to use or sell the asset; the consolidated entity has sufficient resources; and intent to complete the development and its costs can be measured reliably. Capitalised development costs are amortised on a straight-line basis over the period of their expected benefit, being their finite life of 3 years.

(v) Earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the owners of Bioxyne Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of ordinary shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

(w) New and revised accounting requirements applicable to the current half- year reporting period.

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

15

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

2 Critical accounting estimates and judgements

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

(i) Impairment of non-financial assets other than goodwill and other indefinite life intangible assets The consolidated entity assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

(ii) Goodwill and other indefinite life intangible assets The consolidated entity tests annually, or more frequently if events or changes in circumstances indicate impairment, whether goodwill and other indefinite life intangible assets have suffered any impairment, in accordance with the accounting policy stated in note 1(u). The recoverable amounts of cash-generating units have been determined based on value-in-use calculations. These calculations require the use of assumptions, including estimated discount rates based on the current cost of capital and growth rates of the estimated future cash flows.

(iii) Research and development expenditure

The Group has expensed research and development expenditure incurred during the year, where applicable, as the costs relate to the initial expenditure for research and development of biopharmaceutical products where generation of future economic benefits are not considered certain. It was considered appropriate to expense these research and development costs as they did not meet the criteria to be capitalised under AASB 138 Intangible assets.

(iv) Consideration received for divestment and subsequent measurement of Mariposa investment

On the 17[th] June 2015, the shares held in Mariposa Health Limited (‘MHL’) were exchanged for 213,138 shares in Mariposa Health Inc (‘MHI’), a USA Delaware Corporation so that MHL became a subsidiary of MHI. This investment was carried at a cost of $325,000 and was impaired at 30 June 2017.

In additional to the above, part of the total consideration paid to BXN for the disposal of HIPL included a deferred consideration of $1million, payable on achievement of agreed milestones over the next 5 years from 24 February 2014. This has not been recognised in the financial statements. The deferred consideration will be recognised as and when it is received.

The deferred consideration also includes an obligation to pay royalties, which is agreed to be 6.5% of the gross revenue received by the company, MHL or related entities in respect to the sale of the sublicensing or Intellectual property rights, including any sale proceeds or Sub-Royalties. To the extent that products are manufactured based on the intellectual property, royalties are calculated as 2% of Gross revenue.

16

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

(v) Share based payment transactions

The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes model taking into account the terms and conditions upon which the instruments are granted. The accounting estimates and assumptions relating to equity-settled shares-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. Judgment is required in relation to the non-market vesting conditions.

(vi) Estimation of useful lives of assets

The consolidated entity determines the estimated useful lives and related depreciation and amortization charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortization charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

(vii) Income tax

The consolidated entity is subject to income taxes in the jurisdictions in which it operates. Significant judgement is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The consolidate entity recognises liabilities for anticipated tax audit issues based on the consolidated entity’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

3 Revenue from continuing operations Revenue from continuing operations Revenue from contracts with customers and disaggregation Sales of PCC® to USA Wholesale sales nutritional supplements to Asia Sale of goods Direct sales nutritional supplements to Asia	2021 2020 $ $ 2,110,377 2,259,264
	1,815,462 2,142,798 226,561 19,010
	2,042,024 2,161,808
	68,353 97,456

Timing of revenue recognition

All goods are transferred at a point in time, with revenue being recognised on PCC® sales and wholesale sales when goods are shipped, and for direct sales when cash is received.

Geographic regions See note 24.

17

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

4	Other Income
		2021	2020
		$	$
	Research and development tax Incentive	19,147	48,209
	Interest received	18,665	40,067
	Income from royalties	63,138	14,160
	Foreign exchange gain	-	24,684
	Other	11,507	13,475
		112,457	140,595
5	Income tax
		2021	2020
		$	$
	(a) Income tax
	Deferred tax	-	-
		-	-
	(b) Numerical reconciliation of income tax benefit to prima facie tax payable
	Loss from continuing operations before income tax expense	(425,725)	(593,095)
	Tax benefit at the Australian tax rate of 26% (2020 – 27.5%)	(110,688)	(163,101)
	Difference in overseas tax rates	(6,839)	9,600
	Tax effect of amounts which are deductible/not taxable in calculating
	taxable income	28,850	33,447
	Utilisation of tax losses	(99,038)	(129,912)
	Tax effect of adjustments in the prior year		-
	Carried forward tax benefit not recognised	187,715	249,966
	Total income tax expense	-	-
	(c) Tax losses
	Unused tax losses for which no deferred tax asset has been recognised	29,421,993	29,810,334
	Potential tax benefit @ 26% (2020:27.5%)	7,649,718	8,197,842
		2021	2020
		$	$
	6 Cash at bank and in hand	1,602,210	1,747,886
		1,602,210	1,747,886

18

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

7 Trade receivables

Trade receivables
Trade receivables Less: Allowance for expected credit losses Not overdue 0 – 3 months overdue	Expected credit loss rate 2021 % 2020 % 0 0 0 0	2021 2020 $ $ 335,334 304,429 - -
		334,334 304,429
		Carrying Amount
		2021 $ 2020 $
		335,334 304,429 - -
	0 0	335,334 304,429

The trade receivables are largely receivable from the Groups major customer, with which it has been dealing with for many years with no credit losses.

8 Current assets – Current tax receivables

Research and development tax offset receivable GST receivable 9 Current assets – Other current assets Accrued Income and other debtors Royalty receivable Prepayments 10 Current assets – Inventories Work in progress Finished goods 11 Non-current assets – Intangible assets Direct selling licence	2021 2020 $ $ 18,668 34,452 10,145 13,641
	28,813 48,093
	2021 2020 $ $ 35,827 36,065 17,500 - 121,212 165,782
	174,539 201,847
	2021 2020 $ $ 141,068 374,709 298,449 393,233
	439,517 767,942
	2021 2020 $ $ 30,269 30,269
	30,269 30,269

The direct selling licences are current in Indonesia and Malaysia.

19

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

Balance as at 30 June 2019 Amortisation Impairment Balance as at 30 June 2020 Balance as at 30 June 2020 Amortisation Impairment Balance as at 30 June 2021 12 Plant and equipment Cost Opening balance, 1 July 2020 Additions Disposals Foreign exchange adjustment Closing balance, 30 June 2021 Opening balance, 1 July 2019 Additions Disposals Foreign exchange adjustment Closing balance, 30 June 2020 Depreciation Opening balance, 1 July 2020 Depreciation Disposals Foreign exchange adjustment Closing balance, 30 June 2021 Opening balance, 1 July 2019 Depreciation Disposals Foreign exchange adjustment Closing balance, 30 June 2020 Written down value 30 June 2020 Written down value 30 June 2021		Product Development Costs Goodwill Direct Selling Licence Total $ $ $ $ 61,783 151,179 30,269 243,231 (61,783) - - (61,783) - (151,179) - (151,179) - - 30,269 30,269 - - 30,269 30,269 - - - - - - - - - - 30,269 30,269 Plant and equipment Software Leasehold improvements Total
		102,629 101,116 56,060 259,805
		- - - -
		- - - -
		1,399 (1,464) (3,311) (3,376)
		104,028 99,652 52,749 256,429
		87,045 101,401 56,703 245,149 33,662 - - 33,662 (16,727) - - (16,727) (1,351) (285) (643) (2,279)
		102,629 101,116 56,060 259,805
		(38,739) (36,391) (15,420) (90,550)
		(12,426) (19,664) (5,275) (37,365)
		- - - -
		555 378 911 1,844
		(50,610) (55,677) (19,784) (126,071)
		(25,040) (1,451) (9,928) (36,419) (18,971) (35,157) (5,833) (59,961) 4,600 - - 4,600 672 217 341 1,230
		(38,739) (36,391) (15,420) (90,550)
		63,890 64,725 40,640 169,255
		53,418 43,975 32,965 130,358

20

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

13 Leases

• a) Amounts recognised in the balance sheet:

a) Amounts recognised in the balance sheet:
Right-of-use assets Buildings Foreign exchange adjustment Less accumulated depreciation Total right-of-use assets Lease liabilities Current Non-current Total lease liabilities	2021 $ 2020 $ 137,686 137,686 (5,256) - (124,900) (72,068)
	7,530 65,618
	- 47,462 - -
	- 47,462

Additions to the right-of-use assets during the period ended 30 June 2021 was nil.

• b) Amounts recognised in the statement of profit or loss:

Depreciation charge of right-of-use assets Buildings Total right-of-use assets Interest expense (included in borrowing costs) Expenses relating to short-term leases (included in administrative expenses)	2021 $ 2020 $ 49,899 72,068
	49,899 72,068
	2,337 3,133 - -

The total cash outflow for leases during the period ended 30 June 2021 was $46,783 (2020- $52,325).

c) The group’s leasing activities and how these are accounted for:

The group leases various offices with varying lengths between 1 and 3 years, some with extension options.

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants other than the security interests in the leased assets. Leased assets may not be used as security for borrowing purposes.

Until the 2019 financial year, leases of property was classified operating leases. From 1 July 2019, leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group.

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of fixed payments, less any lease incentives receivable.

21

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee’s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

To determine the incremental borrowing rate, the Group:

• where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to reflect changes in financing conditions since third party financing was received;

• uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by the Group, which does not have recent third party financing, and

• makes adjustments specific to the lease, eg term, country, currency and security.

The Group is exposed to potential future increases in variable lease payments based on an index or rate, which are not included in the lease liability until they take effect. When adjustments to lease payments based on an index or rate take effect, the lease liability is reassessed and adjusted against the right-of-use asset.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Right-of-use assets are measured at cost comprising the following:

• the amount of the initial measurement of lease liability;

• any lease payments made at or before the commencement date less any lease incentives received;

• any initial direct costs; and

• restoration costs.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset’s useful life.

Payments associated with short-term leases are recognised on a straight-line basis as an expense in profit or loss (unless capitalised as a component of Plant Construction in Progress). Short-term leases are leases with a lease term of 12 months or less.

Extension options are included in a number of property leases across the Group. These are used to maximise operational flexibility in terms of managing the assets used in the Group’s operations. The extension options held are exercisable only by the Group and not by the respective lessor.

22

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

14 Other financial assets

Non-current Available-for-sale financial assets Less impairment 15 Current liabilities - Trade and other payables Trade creditors Accrued Expenses Other payables 16 Current liabilities - Provisions Provision for annual leave, opening balance Provided during the year Annual leave used Provision for annual leave, closing balance	2021 2020 $ $ 325,000 325,000 (325,000) (325,000)
	- -
	2021 2020 $ $ 175,658 220,227 548,266 375,553 7,803 62,876
	731,727 658,656
	2021 2020 $ $ 20,000 20,000 13,019 - (20,000) -
	13,019 20,000

17 Contributed equity

(a)	Share capital
		2021	2021	2020	2020
		Shares	$	Shares	$
	Ordinary Shares Fully Paid	640,145,398	62,177,536	640,145,398	62,177,536
(b)	Movements in ordinary share capital

Opening balance 1 July 2019 Closing balance 30 June 2020 & 2021	Number of Shares Issue price 640,145,398 640,145,398	$
		62,177,536
		62,177,536

23

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

17 Contributed equity (continued)

(c) Ordinary shares

Each ordinary shareholder maintains, when present in person or by proxy or by attorney at any general meeting of the Company, the right to cast one vote for each ordinary share held.

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amounts paid on the shares held.

(d) Options

As at the date of the financial statements, there were no options over unissued ordinary shares on issue:

(e) Performance rights

Shareholders at the Annual General Meeting on 25 November 2019 resolved to cancel 40,000,000 performance rights granted to the Managing Director, Mr NH Chua, on 3 August 2017, and issue 36,000,000 performance rights to Mr NH Chua.

The performance hurdles for 2019 and 2020 have not been met and have therefore lapsed. The 2022 performance rights of 16 million remain in force. The terms of the performance rights are outlined below.

CEO Performance Rights Terms

The Rights are subject to the following Vesting Conditions which must be satisfied to the satisfaction of the Board (in its discretion), or waived by the Board:

• (a) Mr Chua remaining employed by the Company or one of its subsidiaries for the duration of the Performance Period; and

• (b) Mr Chua meeting the following performance hurdles during the Performance Period, in respect of the percentage of Rights allocated to each hurdle:

• (1) For the year ended 30 June 2020 – 6 million shares on the basis of:

i) Share price hurdle, if the Volume Weighted Average Price is 4 cents for 30 consecutive days in the year to 30 June 2020, the provision of (1)(ii) shall apply.

ii) If Export Sales exceed A$2.0m then 6 million shares plus 4 shares for every A$ of export revenue up to $2.5million.

iii) The maximum shares issued shall be 8 million shares

• (2) For the year ended 30 June 2021 – 10 million shares on the basis of:

(i) Share price hurdle, if the Volume Weighted Average Price is 6.5 cents for 30 consecutive days in the twenty four months preceding 30 June 2021, the provision of (2)(ii) shall apply.

(ii) If Export Sales exceed A$4m then 9 million shares plus 3 shares for every A$1 of sales up to A$5million.

• (iv) The maximum shares issued shall be 12 million shares.

24

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

(e) Performance rights (continued)

(iv) Where cumulative Export Sales for the two years ended 30 June 2021 is more than $7.5 million; any vesting shortfall of Performance Rights pursuant to clause 1 (ii) and 2 (ii) shall vest.

(v) For the avoidance of doubt the maximum vesting of shortfall per 1(ii) and 2 (ii) and 2(iv) shall be 20 million shares.

(3) For the year ended 30 June 2022 – 16 million shares on the basis of:

• (i) Share price hurdle, if the Volume Weighted Average Price is 9 cents for 30 consecutive days in the thirty six months ended 30 June 2022, the provision of 3(ii) shall apply,

• ii) If export sales exceed A$6m then 12 million shares plus 2 shares for every A$1 of sales up to A$8million.

iii) The maximum shares issued shall be 16 million.

The Performance Period commences on 1 July 2019 and ends on 30 June 2022.

The hurdles for the 2021 year were not achieved and no share based payment expense has been recorded for the year ended 30 June 2021.

(e) Capital risk management

The consolidated entity's objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the consolidated entity may adjust the amount of dividends paid to shareholders, return capital to shareholders or issue new shares.

The consolidated entity would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company’s share price at the time of the investment.

The capital management policy remains unchanged from the 30 June 2020 Annual Report.

18 Reserves and accumulated losses (a) Reserves Total reserves Share based payments reserve Movements in share based payments reserve were as follows: Balance 1 July Transfer to share based payments reserve Transfer from share based payments Balance 30 June Movements in foreign currency translation reserve Balance 1 July Movement in foreign currency translation reserve Balance 30 June Total reserves	2021 2020 $ $ (55,749) 123,924
	- 44,762 - - - (44,762)
	- -
	123,924 63,705 (179,673) 60,219
	(55,749) 123,924
	(55,749) 123,924

25

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

(b) Accumulated losses Movements in accumulated losses were as follows: Opening accumulated losses Loss for the year Transfer from share based payments reserve Balance 30 June	2021 2020 $ $ (59,745,101) (59,196,768) (425,725) (593,095) - 44,762
	(60,170,826) (59,745,101)

(c) Nature and purpose of reserves

The share based payment reserve comprises the cumulative value of employee services received through the issue of shares options and performance rights. When the option is exercised or the performance rights vests, the related balance previously recognised in the share based payments reserve is transferred to share capital. When the share options expire or the performance rights lapse, the related balance previously recognised in the share option reserve is transferred to accumulated losses.

19. Non-Controlling Interest

Non-Controlling Interest
Issued capital Retained profits¹	2021 2020
	$ $
	52,861 52,861 - -
	52,861 52,861

The non-controlling interest has a 5% interest in the Indonesian company P.T. Gamata Utama. ¹P.T. Gamata Utama has a small loss for the year which has been borne by the parent company.

20 Interests in other entities

	Country of	Ownership	Ownership
Name of Entity	Incorporation	Interest	Interest	Principal Activities
		2021 %	2020 %
Global Treasure New Zealand	New Zealand	100	100	Product
Limited				development
New Zealand Nutritional Research	New Zealand	100	100	Product research
Institute Limited				and development
Bioxyne International Malaysia	Malaysia	100	100	Sales
Sdn Bhd
Bioxyne International Pty Ltd	Australia	100	100	Intermediate
				holding company
P.T. Gamata Utama	Indonesia	95	95	Sales
Bioxyne International(NZ)Limited	New Zealand	100	100	Sales

21 Remuneration of auditors

Audit services

Audit of financial reports – RSM Australia Partners Total remuneration for audit services	2021 2020 $ $ 63,000 61,000
	63,000 61,000

26

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

22 Commitments

Capital commitments

As at 30 June 2021, the Company has no capital commitments (2020: $nil).

23 Reconciliation of profit after income tax to net cash outflow from operating activities

Loss for the year Depreciation Amortisation right-of-use assets Impairment of intangibles Provision for inventory write down Other non cash items Unrealised foreign exchange loss Change in operating assets and liabilities Decrease in trade and other receivables Decrease/(increase) in inventory Increase/(decrease) in trade and other payables Net cash outflow from operating activities	2021 2020 $ $ (425,725) (593,095) 37,365 59,961 49,899 71,815 - 212,462 - 50,737 22,259 (31,098) 6,599 2,699 15,683 483,562 328,425 (54,324) 18,629 (150,664)
	53,134 52,055

24 Segment information

Bioxyne Limited (ASX:BXN) is an Australian health and wellness products company (incorporated in 2000) with a focus on clinically effective health and wellness products particularly in the gut and immune health areas.

Bioxyne is in the consumer dietary supplements and functional foods markets through its proprietary probiotic, Lactobacillus fermentum VRI-003 (PCC[®] ), and through an acquisition in New Zealand, now trading as Bioxyne International, the Company is further developing a range of functional food and beauty products containing ingredients sourced exclusively from New Zealand, for our direct sales channel.

Bioxyne’s probiotic business is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne has a distribution agreement for PCC[®] with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company.

The Company’s principal operations are to research, develop, market and distribute over the counter dietary supplement products and beauty products.

The Group is organized into two operating segments based on differences in products provided: wholesale sales and direct sales. The operating segments are based on the internal reports that are reviewed and used by Management (who are identified as the Chief Operating Decision Makers (‘CODM’) in assessing performance and in determining the allocation of resources. The CODM is NH Chua the Chief Executive Officer.

Management have determined that it is appropriate to report by sales channel – i.e. either wholesale or direct sales, and by geographical area i.e. USA, Australia and New Zealand, and Asia.

The following table presents revenue and profit information and certain asset and liability information regarding geographical segments for the years ended 30 June 2021 and 30 June 2020.

27

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

24 Segment information (continued)

2021	Wholesale sales Direct sales Unallocated Total USA Asia Australia/NZ Asia
Sales Cost of sales Gross margin Other income Overhead expenses Research and development Profit/(loss) before tax Taxation Profit/(loss) after tax Total assets Total liabilities	1,815,462 65,962 2,391 226,561 - 2,110,377
	(778,897) (19,489) (15,885) (214,772) - (1,029,043)
	1,036,565 46,473 (13,494) 11,789 - 1,081,333
	- - - - 112,457 112,457
	- - - - (1,529,789) (1,529,789
	- - - - (89,726) (89,726)
	1,036,565 46,473 (13,494) 11,789 (1,507,058) (425,725)
	- - - - - -
	1,036,565 46,473 (13,494) 11,789 (1,507,058) (425,725)
Cash Balance Trade receivables Trade and other payables Inventories
	Malaysia Indonesia Australia New Zealand Total
	229,955 573,336 770,813 28,106 - 1,602,210
	44 4,016 261,864 69,410 - 335,334
	11,782 14,332 680,607 25,006 - 731,727
	105,436 34,595 - 299,486 - 439,517

2020	Wholesale sales Direct sales Unallocated Total USA Asia Australia/NZ Asia
Sales Cost of sales Gross margin Other income Overhead expenses Research and development Profit/(loss) before tax Taxation Profit/(loss) after tax Total assets Total liabilities	2,142,798 13,635 5,375 97,456 - 2,259,264 (926,580) (43,814) (1,302) (21,749) (50,737) (1,044,182)
	1,216,218 (30,179) 4,073 75,707 (50,737) 1,215,082 - - - - 140,595 140,595 - - - - (1,818,529) (1,818,529) - - - - (130,243) (130,243)
	1,216,218 (30,179) 4,073 75,707 (1,858,914) (593,095) - - - - - -
	1,216,218 (30,179) 4,073 75,707 (1,858,914) (593,095)

Cash Balance Trade receivables Trade and other payables Inventories	Malaysia Indonesia Australia New Zealand Total
	392,990 691,049 612,398 51,449 1,747,886 46 - 290,627 13,756 304,429 14,348 - 608,245 36,063 658,656 113,455 81,549 34,367 538,571 767,942

28

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

24 Segment information (continued)

Identification of reportable segments

The Group has identified its operating segments based on the internal reports that are reviewed and used by the board of directors in assessing performance and in determining the allocation of resources.

Segment revenues and results

Segment revenue reported above represents revenue generated from external customers.

The accounting policies of the reportable segments are consistent with the Group’s accounting policies described in Note 1. Segment profit represents the profit earned by each segment without allocation of central administration costs and directors’ salaries, share of profits of associates, gain recognised on disposal of interest in former associate, investment income, gains and losses, finance costs and income tax expense. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance.

25 Financial risk management

(a) Financial risk management

The Company’s financial instruments consist mainly of deposits with banks, accounts receivable and payables.

The directors’ overall risk management strategy seeks to assist the Company in meeting its financial targets, whilst minimising potential adverse effects on financial performance.

The Group does not speculate in financial assets.

Credit risk

The Company trades only with recognised, creditworthy third parties. It is the Company’s policy that all customers who wish to trade on credit terms are subject to credit verification procedures. The receivable balances are monitored on an ongoing basis. The Group’s exposure to bad debts is not significant. There is considerable concentration of credit risk within the Company as it only has one major customer at this stage of its development.

With respect to credit risk arising from other financial assets of the Company, which comprise cash and cash equivalents, the Company’s exposure to credit risk arises form default of the counter party, with a maximum exposure equal to the carrying amount of these instruments.

Since the Group trades only with recognised third parties, there is no requirement for collateral security.

The maximum exposure to credit risk at balance date is as follows:

Cash and cash equivalents (Note 6) Trade receivables (Note 7) Research and development tax incentive receivable (Note 9)	2021 2020 $ $ 1,602,210 1,747,886 335,334 304,429 18,668 34,452
	1,956,212 2,086,767

Liquidity risk

The Company’s policy is to maintain a comfortable level of liquidity through the continual monitoring of cash reserves and the raising of additional capital as required.

29

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

25 Financial risk management (continued)

(b) Financial instrument composition and maturity analysis

The table below reflects the undiscounted contractual settlement terms for financial instruments of a fixed period of maturity as well as management’s expectations of the settlement period of all other financial instruments. As such, the amounts may not reconcile to the Statement of Financial Position.

Consolidated Group Financial liabilities - due for payment: Trade and other payables Lease liabilities Total contractual outflows Cash and cash equivalents Trade receivables Total anticipated inflows Net inflow/(outflow) on financial instruments	Within 1year	Within 1year	1 to 5years	1 to 5years	Over 5years	Over 5years	Total	Total
	2021 $	2020 $	2021 $	2020 $	2021 $	2020 $	2021 $	2020 $
		658,656 47,462	- -	- -	- -	- -		658,656 47,462
	731,727						731,727
	-						-
	731,727	706,118	-	-	-	-	731,727	706,118
	1,602,210	1,747,886 304,429	- -	- -	- -	- -	1,602,210	1,747,886 304,429
	335,334						335,334
	1,937,544	2,052,315	-	-	-	-	1,937,544	2,052,315
	1,205,817	1,346,197	-	-	-	-	1,205,817	1,346,197

(c) Net fair values

The net fair value of assets and liabilities approximates their carrying value. No financial assets and liabilities are readily traded on organised markets in standardised form.

The aggregate net fair values and carrying amounts of financial assets and financial liabilities are disclosed in the Statement of Financial Position and notes to the financial statements.

(d) Market risk

Foreign currency risk

The consolidated entity undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange fluctuations.

Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the entity’s functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

30

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

25 Financial risk management (continued)

(e) Sensitivity analysis

The Company has performed a sensitivity analysis relating to its exposure to foreign currency risk at balance date. The effect on profit and equity as a result changes in the value of the Australian Dollar to the US Dollar, and Euro receivables and payables, with all other variables remaining constant, is expected to be minimal.

The effect on profit and equity as a result changes in the value of the Australian Dollar to the US Dollar, Malaysian Ringgit and Indonesian Rupiah and the effect on movement in interest rates is as follows:

2020 Consolidated 2021 Financial Assets Cash and cash equivalents 2020 Financial Assets Cash and cash equivalents Consolidated A$ 5% stronger / (weaker) 2021 Financial Assets Cash in US $ Cash in Euro Cash in IDR Cash in MYR Cash in NZ$ Financial Assets Cash in US $ Cash in Euro Cash in IDR Cash in MYR Cash in NZ$	Carrying Amount $	Interest Rate Risk	Interest Rate Risk
		-1%	+1%
		Profit Equity $ $	Profit Equity $ $
	1,602,210	(16,022) (16,022)	16,022 16,022
	1,747,886	(17,478) (17,478)	17,478 17,478
	Carrying amount in original currency $	Currency Risk	Currency Risk
		5%	-5%
		Profit Equity A$ A$	Profit Equity A$ A$
	543,146	(38,024) (38,024)	38,024 38,024
	15,334	(1,277) (1,277)	1,277 1,277
	6,264,838,341	(30,176) (30,176)	30,176 30,176
	717,874	(12,102) (12,102)	12,102 12,102
	30,199	(1,479) (1,479)	1,479 1,479
		(83,058) (83,058)	83,058 83,058
	311,256 8,633 6,753,622,154 1,154,368 58,547	(21,597) (21,597) (673) (673) (32,907) (32,907) (18,714) (18,714) (2,160) (2,160)	21,597 21,597 673 673 32,907 32,907 18,714 18,714 2,160 2,160
		(76,050) (76,050)	76,050 76,050

31

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

26 Earnings per share
	2021	2020
	Cents	Cents
Basic loss per share (cents per share)	(0.07)	(0.09)
Diluted loss per share (cents per share)	(0.07)	(0.09)
Weighted average number of shares
Basic earnings per share calculation	640,145,398	640,145,398
Diluted earnings per share calculation	640,145,398	640,145,398
Loss for the period used in earnings per share
From continuing operations	(425,725)	(593,095)
27 Share based payments

Options

No share options were issued during the year and no options were outstanding at year end.

Movements in options during the year

Options Balance at beginning of year Exercised during the year Balance at end of year	2021 Weighted Average 2020 Weighted Average
	No. Exercise Price No. Exercise Price
	- - 4,750,000 0.0234 - - (4,750,000)
	- - -

(d) Performance rights

Shareholders at the Annual General Meeting on 25 November 2019 resolved to cancel 40,000,000 performance rights granted to the Managing Director, Mr NH Chua, on 3 August 2017, and issue 36,000,000 performance rights to Mr NH Chua on the terms outlined in note 17.

The hurdles for the years ended 30 June 2021 and 30 June 2020 were not achieved and no expense has been recorded for this financial year. These performance rights have now lapsed leaving 16,000,000 performance rights on issue, with a performance period to 30 June 2022.

32

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

28 Parent entity disclosures

(a) Financial position Total Current Assets Total Assets Total Liabilities EQUITY Contributed equity Reserves Accumulated losses Equity (b) Reserves Option reserve (c) Financial performance Loss for the year Other comprehensive income (d) Commitments 29 Related party transactions	2021 2020 $ $ 2,771,246 2,862,385
	2,802,579 3,406,368
	798,756 797,148
	62,177,536 62,177,536 (3,537) - (60,170,176) (59,568,316)
	2,003,823 2,609,220
	- -
	(425,725) (593,095) - -
	(425,725) (593,095)
	- -

(a) Key management personnel

Refer to the Remuneration Report contained in the Directors Report contained in the Directors Report for details of the remuneration paid or payable to each member of the Group’s key management personnel for the year ended 30 June 2021.

The total remuneration paid to key management personnel of the company and the group during the year is as follows:

Short-term employee benefits Post- employment benefits	2021 2020 $ $ 434,485 386,983 3,642 3,483
	438,127 390,466

33

Bioxyne Limited Notes to the Financial Statements For the year ended 30 June 2021

(b) Transactions with other related parties

During the year the following transactions were undertaken with related parties on an arms’ length basis:

• i. $15,581 (2020-$25,415) was paid to NH Chua a director of the Company as rental for the Malaysian office;

• ii. $60,000 (2020-$56,527) was paid to Jin Chua (a consultant to the Group and daughter of NH Chua a director of the Company) for consulting services.

• iii. $40,000 (2020 - $30,000) was paid to Integrated CFO Solutions Pty Ltd, a company controlled by the Company Secretary, for accounting services.

• iv. Included in accrued expenses, Note 15, is an amount of $122,000 being salary payable to NH Chua a director of the Company.

30 Events subsequent to balance date

No matter or circumstance has arisen since 30 June 2021 that has significantly affected, or may significantly affect:

• a) The Company’s operations in future financial years; or

• b) The results of those operations in future financial years; or

• c) The Company’s state of affairs in future financial years.

31 Economic dependency

The Group has a major customer in the USA, which currently accounts for the majority of the Group’s external sales.

32 Company details

Corporate Head Office and Principal Place of Business

Suite 506, Level 5 50 Clarence Street Sydney NSW 2000

34